Pharmaceuticals News and Research

RSS

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for protection against meningococcal disease in adolescents and adults aged 11-55 years.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Euro funding for diabetes and exercise research

Researchers at The University of Nottingham are among a network of European scientists who have been awarded €12.7 million (around £8.7 million) for a study into the relationship between lack of exercise and the development of diabetes — and the health benefits of regular exercise in its prevention and cure.

12 Jan 2005

Survey finds online health information poised to become important resource for seniors, but not there yet

As the Internet becomes an increasingly important resource for informing decisions about health and health care options, a new national survey of older Americans by the Kaiser Family Foundation finds that less than a third (31%) of seniors (age 65 and older) have ever gone online, but that more than two-thirds (70%) of the next generation of seniors (50-64 year-olds) have done so.

12 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Weight loss may be an early sign of dementia

Dementia-associated weight loss begins before the onset of the definite dementia symptoms and accelerates by the time of the diagnosis, according to a study in the January issue of Archives of Neurology.

10 Jan 2005

Morse code for human cells

Morse code is a simple, effective and clear method of communication and now scientists believe that cells in our body may also be using patterns of signals to switch genes on and off. The discovery may have major implications for the pharmaceutical industry as the signalling molecules that are targeted by drugs may have more than one purpose.

10 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Government should plough drug savings into Pharmaceutical Benefits Scheme (PBS)

Doctors and medicine-makers today called for an expected $280 million Pharmaceutical Benefits Scheme (PBS) windfall to be ploughed into bringing down the price of new cancer and HIV drugs.

9 Jan 2005

FDA approves Abraxane for metastatic breast cancer

American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.

9 Jan 2005

Fallout from Vioxx and Celebrex market recall challenges industry

The pharmaceutical and biotechnology industries face further marketing and sales challenges in 2005 as the fallout from the Vioxx and Celebrex market recall and warning make it increasingly challenging for companies across the industry to reach physicians and consumers with effective campaigns without the distractions of the unfavorable press these recent events have generated.

7 Jan 2005

First program to apply RNA interference (RNAi) technology to asthma

Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.

7 Jan 2005

Researchers want to see physicians reevaluate the drugs their elderly patients take to determine if they are appropriate

Just as our bodies physically slow down as we age, changes occur in the way that older bodies handle pharmaceuticals, and prescribing physicians need to be aware of those medications inappropriate for the elderly.

6 Jan 2005

Antibiotics protect nerves in mice by turning on genes

A family of antibiotics that includes penicillin may help prevent nerve damage and death in a wide variety of neurological diseases, including Lou Gehrig's disease, dementia, stroke, and epilepsy, Johns Hopkins researchers have found.

6 Jan 2005

States to explore putting restrictions on AIDS drug Trizivir

AIDS Healthcare Foundation (AHF) has sent a letter dated October 20, 2004, to the heads of all state Medicaid programs asking them put in use treatment authorization request (TAR) procedures on GlaxoSmithKline's (GSK) fixed-dose combination AIDS drug, Trizivir, as a standalone regimen for treatment naïve patients.

6 Jan 2005

Chamomile tea shown to boost the immune system and fight infections associated with colds

For centuries, people who’ve felt sick or stressed have tried drinking chamomile tea as a medicinal cure-all. Now, researchers in England have found new evidence that the popular herbal tea may actually help relieve a wide range of health ailments, including colds and menstrual cramps.

5 Jan 2005

Genaissance patent for novel methods to correlate genetics with drug safety and efficacy

Genaissance Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming methods for identifying correlations between the safety and efficacy of drugs and patients' unique genetic signatures.

4 Jan 2005

First new leukemia treatment approved specifically for children in more than a decade

Ash Stevens was approved to manufacture the bulk drug substance Clofarabine, the active ingredient in Genzyme Corp.'s Clolar (clofarabine) for the treatment of children with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). This is the first new leukemia treatment approved specifically for children in more than a decade.

4 Jan 2005

Pharmaceuticals News and Research

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Avastin available across Europe within the next few weeks

Euro funding for diabetes and exercise research

Survey finds online health information poised to become important resource for seniors, but not there yet

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

Weight loss may be an early sign of dementia

Morse code for human cells

Potential new therapies for cancer and bleeding disorders

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Government should plough drug savings into Pharmaceutical Benefits Scheme (PBS)

FDA approves Abraxane for metastatic breast cancer

Fallout from Vioxx and Celebrex market recall challenges industry

First program to apply RNA interference (RNAi) technology to asthma

Researchers want to see physicians reevaluate the drugs their elderly patients take to determine if they are appropriate

Antibiotics protect nerves in mice by turning on genes

States to explore putting restrictions on AIDS drug Trizivir

Chamomile tea shown to boost the immune system and fight infections associated with colds

Genaissance patent for novel methods to correlate genetics with drug safety and efficacy

First new leukemia treatment approved specifically for children in more than a decade

Industry Focus - Biopharma eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News